A detailed history of Intact Investment Management Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Intact Investment Management Inc. holds 700 shares of VRTX stock, worth $329,252. This represents 0.01% of its overall portfolio holdings.

Number of Shares
700
Holding current value
$329,252
% of portfolio
0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$460.0 - $505.78 $322,000 - $354,046
700 New
700 $325,000
Q4 2023

Feb 02, 2024

SELL
$343.0 - $410.68 $205,800 - $246,408
-600 Reduced 24.0%
1,900 $773,000
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $169,090 - $181,230
500 Added 25.0%
2,500 $869,000
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $125,768 - $140,764
-400 Reduced 16.67%
2,000 $703,000
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $685,824 - $771,552
2,400 New
2,400 $693,000
Q2 2022

Aug 11, 2022

SELL
$234.96 - $292.55 $46,992 - $58,510
-200 Reduced 7.14%
2,600 $733,000
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $354,272 - $417,552
-1,600 Reduced 36.36%
2,800 $731,000
Q4 2021

Feb 11, 2022

SELL
$177.01 - $223.45 $106,206 - $134,070
-600 Reduced 12.0%
4,400 $966,000
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $1.04 Million - $1.21 Million
5,000 New
5,000 $1.07 Million
Q4 2018

Jan 22, 2019

SELL
$151.91 - $192.21 $180,772 - $228,729
-1,190 Closed
0 $0
Q3 2018

Oct 29, 2018

SELL
$167.73 - $192.74 $36,900 - $42,402
-220 Reduced 15.6%
1,190 $229,000
Q2 2018

Jul 25, 2018

BUY
$145.72 - $169.96 $2,914 - $3,399
20 Added 1.44%
1,410 $240,000
Q1 2018

May 08, 2018

SELL
$151.6 - $177.13 $31,836 - $37,197
-210 Reduced 13.13%
1,390 $227,000
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $27,456 - $31,110
200 Added 14.29%
1,600 $240,000
Q3 2017

Oct 27, 2017

BUY
$148.13 - $162.24 $207,382 - $227,136
1,400
1,400 $213,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Intact Investment Management Inc. Portfolio

Follow Intact Investment Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Intact Investment Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Intact Investment Management Inc. with notifications on news.